Primary failure of bortezomib in newly diagnosed multiple myeloma – understanding the magnitude, predictors, and significance

References

• Moreau P, Richardson PG, Cavo M, et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood 2012;120:947–959.
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol. 2010;28:4621–4629.
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Schmidt-Wolf IGH, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol. 2012;30:2946–2955.
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906–917.
   PubMed Web of Science ®Google Scholar
• Niesvizky R, Flinn IW, Rifkin R, et al. Efficacy and safety of three bortezomib-based combinations in elderly, newly diagnosed multiple myeloma patients: results from all randomized patients in the community-based, phase 3b UPFRONT study. Blood. 2011;118: Abstract 478.
   Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Rossi D, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol. 2010;28:5101–5109.
   PubMed Web of Science ®Google Scholar
• Reeder CB, Reece DE, Kukreti V, et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia 2009;23:1337–1341.
   PubMed Web of Science ®Google Scholar
• Durie BGM, Harousseau J-L, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467–1473.
   PubMed Web of Science ®Google Scholar
• Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 2011;29:532–543.
   PubMed Web of Science ®Google Scholar
• Evens AM, Kostakoglu L. The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease. Hematology Am Soc Hematol Educ Program. 2015;124:135–143.
   Google Scholar
• Murray MY, Auger MJ, Bowles KM. Overcoming bortezomib resistance in multiple myeloma. Biochem Soc Trans. 2014;42:804–808.
   PubMed Web of Science ®Google Scholar
• Greipp PR, Miguel JS, Dune BGM, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412–3420.
   PubMed Web of Science ®Google Scholar
• Zhuang J, Da Y, Li H, et al. Cytogenetic and clinical risk factors for assessment of ultra high-risk multiple myeloma. Leuk Res. 2014;38:188–193.
   PubMed Web of Science ®Google Scholar
• Chng WJ, Dispenzieri a, Chim C-S, et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia 2014;28:269–277. doi:10.1038/leu.2013.247
   PubMed Web of Science ®Google Scholar
• Ludwig H, Miguel JS, Dimopoulos Ma, et al. International Myeloma Working Group recommendations for global myeloma care. Leukemia 2014;28:981–992.
   PubMed Web of Science ®Google Scholar
• Moreau P, Avet-loiseau H, Facon T, et al. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood 2011;118:5752–5758.
   PubMed Web of Science ®Google Scholar
• Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010;376: 2075–2085.
   PubMed Web of Science ®Google Scholar
• Cavo M, Rajkumar SV, Palumbo A, et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood 2011;117:6063–6073.
   PubMed Web of Science ®Google Scholar
• Benboubker L, Dimopoulos MA, Dispenzieri A, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014;371:906–917.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Magarotto V, Bringhen S, et al. A randomized phase 3 trial of melphalan-lenalidomide-prednisone (MPR) or cyclophosphamide-prednisone-lenalidomide (CPR) vs. lenalidomide plus dexamethasone (Rd) in elderly newly diagnosed multiple myeloma patients. Blood. 2013;122: Abstract 536.
   Google Scholar
• Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61:3071–3076.
   PubMed Web of Science ®Google Scholar
• Landis-Piwowar KR, Milacic V, Chen D, et al. The proteasome as a potential target for novel anticancer drugs and chemosensitizers. Drug Resist Update. 2006;9:263–273.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Rajkumar SV, San Miguel JF, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol. 2014; 32:587–600.
   PubMed Web of Science ®Google Scholar
• Hari P, Vij R, Zhang MJ, et al. Non-response to initial MM induction – is there benefit to additional therapy to upgrade response pre-transplant (AHCT)? Clin Lymphoma Myeloma Leuk. 2013;13:S115.
   Google Scholar